Home
overview

We are pleased to announce our forthcoming European Pharmaceutical Pricing & Reimbursement conference on the 21 & 22 October. Now in its 19th year, this event has been one of the oldest market leaders in the pharmaceutical industries calendar for some time.


Our expert speaking faculty; made up from key industry personnel from big pharma, biotech and academia will thoroughly explain and offer advice on P&R and market access. The 2013 agenda will focus on European and US markets including country specific case studies proving strategic insight into how a wide range of complex issues can be readily adapted to.
 

Future product release requires a well thought out and cross sector integrated market access strategy - Economic value in product development is now paramount in reimbursement. Allow P&R 2013 to provide you with the most comprehensive up to date centre of information with reimbursement evidence in product development; Impact of HTA in different markets and international based price referencing.

How will value based pricing affect the economic market in the U.K? This long discussed format has a number of looming deadlines for progression and looks to be taking gradual steps forward, with new PPBS taking the fore in covering some products. See how these formats can affect your product and where exactly they will lead.

Our expert speaking faculty have been integrated together to give you the most up to date developments on Pricing & Reimbursement in the pharmaceutical sector. Ranging from experience in big pharma, academia and biotech companies with hundreds of years of accumulated experience allow P&R 2013 to show you how exactly you can navigate an extremely hostile market.

  • Understand how value based pricing will affect the U.Ks pricing market and what to expect
  • Discuss key market access strategies within a range of case studies e.g. those currently being developed successfully in Orphan Drugs
  • Evaluate strategies that are being deployed in emerging markets
  • See how AMNOG has affected German markets
  • Develop future cross sector market access strategies
   

• Market Access
• Launch Excellence
• Pricing and Reimbursement
• Marketing (Consumer, Relationship, Multi channel,Strategic)
• Project Management
• Value Based Pricing
• Business Development
• Patient Advocacy
• Medical Information & Education
• CRM
• Business Analysis
• eMarketing
• Pharmacy Operations
• Specialty and Orphan drugs market
• Patient communications
• Health economics and outcomes research
• External affairs
 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Donald Macarthur

Donald Macarthur, Global Pharmaceutical Business Analyst, JustPharmaReports

9:10 Value Based Pricing

Leslie Galloway

Leslie Galloway, Chairman, Ethical Medicines Industry Group

Implications for PPRS
What is outside the negotiations?
How will value be measured?

9:50 Implications of requiring traditional health economic assessments when evaluating ultra-orphan drugs

Sarah Pitluck

Sarah Pitluck, Senior Director, Global Pricing & Reimbursement, Alexion Pharmaceuticals Inc

  • Traditional cost-effectiveness analyses are not an appropriate method to evaluate ultra-orphan drugs and can have a negative impact on patient access to treatments
  • Countries that require traditional economic analyses inappropriately disadvantage patients with ultra-rare diseases
  • Instead, review agencies should look at a combination of other factors when evaluating such drugs
  • 10:30 Morning Coffee

    11:00 Establishment of the permanent pan-European HTA network: implications for HTA and coverage decision making

    Franz Pichler

    Franz Pichler, Director, Global Public Policy, Eli Lilly & Co

  • Timeline and process to the establishment of the network
  • The role of EUnetHTA in terms of operational implementing
  • Key activities proposed for the network and implications of these activities for pharma
  • 11:40 The challenge of value delivery

    Janice Haigh

    Janice Haigh, Practice Leader, Market Access, Quintiles

  • How do global value messages translate in the local environment?
  • What types of value messages best support local negotiations?
  • How do we make sure that the reimbursement price agreed at national level becomes the realised price at local level?
  • 12:20 Networking Lunch

    13:50 Integration of Health-Economics and Market Access in the development of innovative drugs

    Patrick Mollon

    Patrick Mollon, Director Health-Economics & Outcomes Research, Novartis

  • Value-Based Development: need and opportunities to demonstrate value
  • Health-Economic strategies to anticipate Market Access needs
  • Methods and Tools supporting value evidence generation
  • 14:30 New Evidence on the Effectiveness Gap; How Pharma can deliver

    Nick Bosanquet

    Nick Bosanquet, Professor of Health Policy, Imperial College London

  • The current problem: case studies in COPD and cancer
  • International comparisons of the effectiveness gap—France,UK,Germany and Finland
  • Partnership with pharma and health services  to deliver therapeutic results
  • 15:10 Key learnings of 2 years of AMNOG

    Bertram Häussler

    Bertram Häussler, Director, IGES Institut.

  • Pricing and additional benefit
  • Do innovative drugs still have a chance?
  • Roadblocks moving forward
  • Case study
  • 15:50 Chairman’s Closing Remarks and Close of Day One

    16:00 Afternoon Tea

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Donald Macarthur

    Donald Macarthur, Global Pharmaceutical Business Analyst, JustPharmaReports

    9:10 The new NICE and its global network

    Anne-Toni Rodgers

    Anne-Toni Rodgers, Global Payer Lead, AstraZeneca

  • A new Leadership … a New NICE?
  • A UK Government Export  - understand how NICE proactively shapes the Pricing & Reimbursement environment internationally
  • Plan your global response
  • 9:50 Reform of the EU transparency directive

    Strati Sakellariou

    Strati Sakellariou, Associate, White & Case LLP

  • The push for reform – issues not covered in the 1989 Directive
  • The content and status of the reform proposal
  • Next steps – when the changes will take effect in practice
  • 10:30 Morning Coffee

    11:00 No-one benefits from flying with empty planes: What options do we have to improve access in oncology? Experiences from Scandinavia

    Peter Hertzman

    Peter Hertzman, Nordic Market Access Director, Bristol Myers Squibb

  • Patients are benefiting from many new and exciting innovative oncology products. However, the discrepancies between providers’ and payors’ expectations have still to be resolved.
  • There are various contractual options tested out in reality in order to resolve the discrepancies. What are the pros and cons with these options
  • Examples of the above from the Scandinavian markets
  • 11:40 Japan: The Land that Cost Containment Forgot

    Donald Macarthur

    Donald Macarthur, Global Pharmaceutical Business Analyst, JustPharmaReports

  • Pricing environment in Japan vs leading western countries
  • Price comparisons
  • Market entry strategies
  • Prospects for change
  • 12:20 Networking Lunch

    13:50 Pricing of pharmaceuticals in a resource constrained environment

    Ceri Phillips

    Ceri Phillips, Professor of Health Economics and Head of Swansea Centre for Health Economics, Swansea University

  • Healthcare policies in a period of recession
  • Policies relating to pharmaceuticals during recessionary periods
  • New initiatives in pharmaceutical pricing
  • The role of HTA
  • 14:30 Panel Discussion:European Pricing & Reimbursement going forwards

    Leslie Galloway

    Leslie Galloway, Chairman, Ethical Medicines Industry Group

    Anne-Toni Rodgers

    Anne-Toni Rodgers, Global Payer Lead, AstraZeneca

    15:10 Chairman’s Closing Remarks and Close of Day Two

    15:20 Afternoon Tea

    +

    FEATURED SPEAKERS

    Janice Haigh

    Janice Haigh

    Practice Leader, Market Access, Quintiles
    Leslie Galloway

    Leslie Galloway

    Chairman, Ethical Medicines Industry Group
    Peter Hertzman

    Peter Hertzman

    Nordic Market Access Director, Bristol Myers Squibb
    Sarah Pitluck

    Sarah Pitluck

    Senior Director, Global Pricing & Reimbursement, Alexion Pharmaceuticals Inc

    Anne-Toni Rodgers

    Global Payer Lead, AstraZeneca
    Anne-Toni Rodgers

    Bertram Häussler

    Director, IGES Institut.
    Bertram Häussler

    Ceri Phillips

    Professor of Health Economics and Head of Swansea Centre for Health Economics, Swansea University
    Ceri Phillips

    Donald Macarthur

    Global Pharmaceutical Business Analyst, JustPharmaReports
    Donald Macarthur

    Franz Pichler

    Director, Global Public Policy, Eli Lilly & Co
    Franz Pichler

    Janice Haigh

    Practice Leader, Market Access, Quintiles
    Janice Haigh

    Leslie Galloway

    Chairman, Ethical Medicines Industry Group
    Leslie Galloway

    Nick Bosanquet

    Professor of Health Policy, Imperial College London
    Nick Bosanquet

    Patrick Mollon

    Director Health-Economics & Outcomes Research, Novartis
    Patrick Mollon

    Peter Hertzman

    Nordic Market Access Director, Bristol Myers Squibb
    Peter Hertzman

    Sarah Pitluck

    Senior Director, Global Pricing & Reimbursement, Alexion Pharmaceuticals Inc
    Sarah Pitluck

    Strati Sakellariou

    Associate, White & Case LLP
    Strati Sakellariou

    Stratigoula Sakellariou

    Associate, White & Case LLP
    Stratigoula Sakellariou

    Workshops

    HTA Uncovered
    Workshop

    HTA Uncovered

    Holiday Inn Regents Park
    23rd October 2013
    London, United Kingdom

    Holiday Inn Regents Park

    Carburton Street
    London W1W 5EE
    United Kingdom

    Holiday Inn Regents Park

    Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

    Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

    Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.